269 Results for "

ADC Linker Inhibitors

" in MedChemExpress (MCE) Product Catalog:
Products (269)

269 Results for "ADC Linker Inhibitors" in MCE Product Catalog:

97
97 Publications Verification
Cat. No.: HY-15575
CAS No.: 646502-53-6
Purity:  99.94%
Synonyms: MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-19792
CAS No.: 139504-50-0
Synonyms: DM1; Maytansinoid DM1
Research Areas:  

Cancer

Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-138298
CAS No.: 1826843-81-5
Purity:  98.90%
Synonyms: T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-138298A
CAS No.: 1826843-81-5
Purity:  99.58%
Synonyms: T-DXd; DS-8201; DS-8201a
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-15578
CAS No.: 863971-19-1
Purity:  99.96%
Synonyms: Maleimidocaproyl monomethylauristatin F
Research Areas:  

Cancer

McMMAF (Maleimidocaproyl monomethylauristatin F) is an active molecule linker for ADC, made by coupling the powerful microtubule inhibitor Monomethyl auristatin F (MMAF) (HY-15579) with the protecting group maleimidocaproyl. McMMAF can be conjugated with anti-BCMA antibodies to form J6M0-mcMMAF, promoting apoptosis and inhibiting tumor growth .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-128946
CAS No.: 1279680-68-0
Purity:  99.07%
CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-114233
CAS No.: 1600418-29-8
Purity:  99.71%
Synonyms: MC-GGFG-DX8951
Research Areas:  

Cancer

MC-GGFG-Exatecan (MC-GGFG-DX8951) is a agent-linker conjugate for ADC. MC-GGFG-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with protease cleavable MC-GGFG linker. MC-GGFG-Exatecan shows antitumor activity and can be used to prepare DX8951 antibody conjugate (ADC) .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-112786
CAS No.: 863971-17-9
Purity:  98.16%
Synonyms: Vc-MMAF
Research Areas:  

Cancer

MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P9985
CAS No.: 2136633-23-1
Synonyms: RC48
Research Areas:  

Cancer

Disitamab vedotin (RC48) is a HER2-targeted antibody-drug conjugate (ADC), formed by conjugation of the humanized anti-HER2 antibody Disitamab (HY-P99854) with drug-linker VcMMAE (HY-15575). VcMMAE consists of a cleavable MC-Val-Cit-PAB linker and the microtubule inhibitor MMAE (HY-15162). After binding to HER2 and undergoing endocytosis, Disitamab vedotin releases MMAE in lysosomes, which further inhibits microtubule assembly, arrests mitosis and induces apoptosis, while also exerting a bystander effect. Disitamab vedotin can be used in studies of HER2-positive breast cancer .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-100874
CAS No.: 3046395-46-1
Purity:  98.56%
Research Areas:  

Cancer

N3-PEG3-vc-PAB-MMAE is a synthesized agent-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity. N3-PEG3-vc-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-12460
CAS No.: 1626359-62-3
Purity:  98.14%
Research Areas:  

Cancer

SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-100566
Purity:  99.24%
Research Areas:  

Cancer

SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-114816
CAS No.: 67605-85-0
Purity:  98.77%
Synonyms: C4-HSL; N-Butyryl-L-homoserine lactone
Target:  

ADC Linkers Bacterial

Research Areas:  

Infection Inflammation/Immunology

N-Butanoyl-L-homoserine lactone (C4-HSL) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has antibacterial activity and is used in antibacterial biofilm . N-Butanoyl-L-homoserine lactone aptamers blocks qurom sensing and inhibits biofilm formation in Pseudomonas aeruginosa .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P9980
CAS No.: 2061894-48-0
Synonyms: GSK2857914

Research Areas:  

Cancer

Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-100374
CAS No.: 644981-35-1
Purity:  99.76%
Research Areas:  

Cancer

Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-147239
CAS No.: 1818864-51-5
Purity:  99.93%
Research Areas:  

Cancer

MC-VA-PABC-MMAE is a agent-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-126681
CAS No.: 2259318-46-0
Purity:  98.01%
Synonyms: NHS-VC-PAB-MMAE
Research Areas:  

Cancer

SC-VC-PAB-MMAE (NHS-VC-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-131057
CAS No.: 1801838-28-7
Purity:  96.38%
Research Areas:  

Cancer

Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-134723
CAS No.: 2694856-51-2
Purity:  98.42%
Research Areas:  

Cancer

DBCO-PEG4-GGFG-Dxd is a agent-linker conjugate for ADC with potent antitumor activity by using Dxd (a DNA topoisomerase I inhibitor), linked via the cleavable ADC linker DBCO-PEG4-GGFG . DBCO-PEG4-GGFG-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-136170
CAS No.: 1473403-87-0
Purity:  98.94%
Research Areas:  

Cancer

MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, inhibits DNA synthesis and causes frequent DNA single-strand breaks .
loading...
    loading...